Institutional Investors Lead Shift in Catalent (NYSE:CTLT) Sentiment

June 14, 2018 - By Marry Poplack

Catalent, Inc. (NYSE:CTLT) Logo

Sentiment for Catalent (NYSE:CTLT)

Catalent (NYSE:CTLT) institutional sentiment decreased to 1.16 in 2018 Q1. Its down -0.28, from 1.44 in 2017Q4. The ratio worsened, as 125 active investment managers increased and started new holdings, while 108 cut down and sold stock positions in Catalent. The active investment managers in our partner’s database now possess: 127.42 million shares, down from 130.69 million shares in 2017Q4. Also, the number of active investment managers holding Catalent in their top 10 holdings increased from 1 to 4 for an increase of 3. Sold All: 23 Reduced: 85 Increased: 88 New Position: 37.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. The company has market cap of $5.45 billion. It operates through three divisions: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. It has a 74.6 P/E ratio. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

The stock increased 1.54% or $0.62 during the last trading session, reaching $40.88. About 343,524 shares traded. Catalent, Inc. (NYSE:CTLT) has risen 9.81% since June 14, 2017 and is uptrending. It has underperformed by 2.76% the S&P500.

Analysts await Catalent, Inc. (NYSE:CTLT) to report earnings on August, 27. They expect $0.58 EPS, down 9.38 % or $0.06 from last year’s $0.64 per share. CTLT’s profit will be $77.35 million for 17.62 P/E if the $0.58 EPS becomes a reality. After $0.38 actual EPS reported by Catalent, Inc. for the previous quarter, Wall Street now forecasts 52.63 % EPS growth.

Price Capital Management Inc. holds 7.62% of its portfolio in Catalent, Inc. for 93,458 shares. Bernzott Capital Advisors owns 808,565 shares or 4.31% of their US portfolio. Moreover, Champlain Investment Partners Llc has 1.61% invested in the company for 3.63 million shares. The Illinois-based Fortaleza Asset Management Inc has invested 1.58% in the stock. Bluemar Capital Management Llc, a New York-based fund reported 74,816 shares.

Since January 1, 0001, it had 0 buys, and 1 sale for $379,628 activity.

Catalent, Inc. (NYSE:CTLT) Ratings Coverage

Ratings analysis reveals 63% of Catalent’s analysts are positive. Out of 8 Wall Street analysts rating Catalent, 5 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $44.0 while the high is $50. The stock’s average target of $47.20 is 15.46% above today’s ($40.88) share price. CTLT was included in 8 notes of analysts from January 8, 2018. Stephens downgraded Catalent, Inc. (NYSE:CTLT) on Tuesday, February 6 to “Hold” rating. RBC Capital Markets maintained the shares of CTLT in report on Monday, February 5 with “Buy” rating. Raymond James upgraded the shares of CTLT in report on Wednesday, March 21 to “Outperform” rating. The stock of Catalent, Inc. (NYSE:CTLT) earned “Overweight” rating by KeyBanc Capital Markets on Wednesday, March 28. The firm has “Hold” rating by Jefferies given on Monday, February 5. Bank of America maintained the shares of CTLT in report on Tuesday, February 6 with “Buy” rating.

Catalent, Inc. (NYSE:CTLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: